Pathophysiology of anthracycline cardiotoxicity

Donato Mele, Carlo G. Tocchetti, Pasquale Pagliaro, Rosalinda Madonna, Giuseppina Novo, Alessia Pepe, Concetta Zito, Nicola Maurea, Paolo Spallarossa

Research output: Contribution to journalArticle

Abstract

Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.

Original languageEnglish
Pages (from-to)S3-S11
JournalJournal of Cardiovascular Medicine
Volume17
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Anthracyclines
Pharmaceutical Preparations
Left Ventricular Dysfunction
Heart Failure
Mortality
Cardiotoxicity
Neoplasms
Therapeutics

Keywords

  • anthracyclines
  • cancer
  • cardiotoxicity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mele, D., Tocchetti, C. G., Pagliaro, P., Madonna, R., Novo, G., Pepe, A., ... Spallarossa, P. (2016). Pathophysiology of anthracycline cardiotoxicity. Journal of Cardiovascular Medicine, 17, S3-S11. https://doi.org/10.2459/JCM.0000000000000378

Pathophysiology of anthracycline cardiotoxicity. / Mele, Donato; Tocchetti, Carlo G.; Pagliaro, Pasquale; Madonna, Rosalinda; Novo, Giuseppina; Pepe, Alessia; Zito, Concetta; Maurea, Nicola; Spallarossa, Paolo.

In: Journal of Cardiovascular Medicine, Vol. 17, 01.05.2016, p. S3-S11.

Research output: Contribution to journalArticle

Mele, D, Tocchetti, CG, Pagliaro, P, Madonna, R, Novo, G, Pepe, A, Zito, C, Maurea, N & Spallarossa, P 2016, 'Pathophysiology of anthracycline cardiotoxicity', Journal of Cardiovascular Medicine, vol. 17, pp. S3-S11. https://doi.org/10.2459/JCM.0000000000000378
Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A et al. Pathophysiology of anthracycline cardiotoxicity. Journal of Cardiovascular Medicine. 2016 May 1;17:S3-S11. https://doi.org/10.2459/JCM.0000000000000378
Mele, Donato ; Tocchetti, Carlo G. ; Pagliaro, Pasquale ; Madonna, Rosalinda ; Novo, Giuseppina ; Pepe, Alessia ; Zito, Concetta ; Maurea, Nicola ; Spallarossa, Paolo. / Pathophysiology of anthracycline cardiotoxicity. In: Journal of Cardiovascular Medicine. 2016 ; Vol. 17. pp. S3-S11.
@article{fecaf6b7099e4891b071e4c66cd0c23c,
title = "Pathophysiology of anthracycline cardiotoxicity",
abstract = "Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.",
keywords = "anthracyclines, cancer, cardiotoxicity",
author = "Donato Mele and Tocchetti, {Carlo G.} and Pasquale Pagliaro and Rosalinda Madonna and Giuseppina Novo and Alessia Pepe and Concetta Zito and Nicola Maurea and Paolo Spallarossa",
year = "2016",
month = "5",
day = "1",
doi = "10.2459/JCM.0000000000000378",
language = "English",
volume = "17",
pages = "S3--S11",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Pathophysiology of anthracycline cardiotoxicity

AU - Mele, Donato

AU - Tocchetti, Carlo G.

AU - Pagliaro, Pasquale

AU - Madonna, Rosalinda

AU - Novo, Giuseppina

AU - Pepe, Alessia

AU - Zito, Concetta

AU - Maurea, Nicola

AU - Spallarossa, Paolo

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.

AB - Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.

KW - anthracyclines

KW - cancer

KW - cardiotoxicity

UR - http://www.scopus.com/inward/record.url?scp=84969941505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969941505&partnerID=8YFLogxK

U2 - 10.2459/JCM.0000000000000378

DO - 10.2459/JCM.0000000000000378

M3 - Article

AN - SCOPUS:84969941505

VL - 17

SP - S3-S11

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

ER -